Vical Inc. is presenting a strong rationale advocating the use of DNA vaccine technology for emerging and/or pandemic infectious diseases. Highlights historical data from multiple human clinical trials of DNA vaccines demonstrating safety, broad immunogenicity, and initial indications of efficacy. A favorable safety profile has been established through testing of various DNA vaccines in human subjects now totaling in the thousands. Recent studies of DNA vaccines formulated with Vical's Vaxfectin(R) adjuvant or polaxamers have shown clear ability to elicit both antibody and T-cell immune response. These advantages, coupled with rapid development speed, excellent flexibility, and manufacturing which is not dependent upon cell culture or chicken eggs, encourage the use of DNA vaccine technology for emerging threats such as the recent H1N1 swine flu and other emerging diseases.

Vical Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2009. The company reported revenues for the third quarter of 2009 increased to $3.9 million, compared with revenues of $0.8 million for the third quarter of 2008, primarily as a result of increased revenue from AnGes MG Inc., related to funding of the company's Phase 3 Allovectin-7 trial, and contract manufacturing revenues for the delivery of a dengue vaccine to the U.S. Navy. The net loss was $7.0 million or $0.14 per basic and diluted share, compared with $9.8 million or $0.24 per basic and diluted share for the third quarter of 2008. Revenues for the first nine months of 2009 were $10.1 million, compared with revenues of $5.3 million for the first nine months of 2008. The net loss was $21.2 million, or $0.47 per basic and diluted share, compared with a net loss of $27.9 million, or $0.70 per basic and diluted share, for the first nine months of 2008. The decrease in net loss reflected the increased revenues as well as operational improvements resulting from the strategic restructuring implemented in November 2008. The company provided cash flow guidance for the full year 2009. The company's guidance of a full-year 2009 net cash burn of between $19 million and $23 million.

Vical Inc., Q3 2009 Earnings Call, Nov-04 2009